drugset / Trial / NCT00770367
Pioglitazone and Serum Asymmetric Dimethylarginine (ADMA) in Patients With Diabetes
Phase 4
Completed
36 enrolled
Medical University of South Carolina
Takeda Pharmaceuticals North America, Inc. · collab
RandomizedCrossoverQuadruple-blindPrevention
Summary
SPECIFIC AIMS 1. To determine whether pioglitazone will reduce levels of asymmetric dimethylarginine(ADMA) in patients with diabetes. 2. To determine whether nitric oxide(NOx) products are increased with pioglitazone treatment. 3. To determine whether pioglitazone reduces oxidative stress (F2-isoprostanes).
Timeline
- Start
- 2008-10
- Primary completion
- 2009-12
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pioglitazone | Small molecule | 30 mg | — |